Roeland  Nusse net worth and biography

Roeland Nusse Biography and Net Worth

Director of Bio-Techne
Roeland Nusse, Ph.D., has served on the Company's Board since May 2010. Dr. Nusse has served as Chairman of the Department of Developmental Biology at Stanford University since 2007. Dr. Nusse has been a professor or associate professor in the Department of Developmental Biology at Stanford University and an investigator at the Howard Hughes Medical Institute since 1990. He has also been the chair of the Department of Developmental Biology at Stanford since 2007. Dr. Nusse was previously at the Netherlands Cancer Institute (Amsterdam, The Netherlands) as a staff scientist and ultimately head of the Department of Molecular Biology. Dr. Nusse was elected to the United States National Academy of Sciences in April 2010. Dr. Nusse was previously named a member of the European Molecular Biology Organization in 1988, a member of the Royal Dutch Academy of Sciences in 1997 and a member of the American Academy of Arts and Sciences in 2001.

What is Roeland Nusse's net worth?

The estimated net worth of Roeland Nusse is at least $3.59 million as of August 30th, 2023. Dr. Nusse owns 51,872 shares of Bio-Techne stock worth more than $3,588,505 as of December 11th. This net worth evaluation does not reflect any other assets that Dr. Nusse may own. Learn More about Roeland Nusse's net worth.

How do I contact Roeland Nusse?

The corporate mailing address for Dr. Nusse and other Bio-Techne executives is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. Bio-Techne can also be reached via phone at (612) 379-8854 and via email at [email protected]. Learn More on Roeland Nusse's contact information.

Has Roeland Nusse been buying or selling shares of Bio-Techne?

Roeland Nusse has not been actively trading shares of Bio-Techne during the past quarter. Most recently, Roeland Nusse sold 8,939 shares of the business's stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $80.32, for a transaction totalling $717,980.48. Following the completion of the sale, the director now directly owns 51,872 shares of the company's stock, valued at $4,166,359.04. Learn More on Roeland Nusse's trading history.

Who are Bio-Techne's active insiders?

Bio-Techne's insider roster includes Robert Baumgartner (Director), Norman Eansor (Insider), Brenda Furlow (SVP), John Higgins (Director), James Hippel (CFO), Kim Kelderman (Insider), Charles Kummeth (CEO), Roeland Nusse (Director), and Alpna Seth (Director). Learn More on Bio-Techne's active insiders.

Are insiders buying or selling shares of Bio-Techne?

In the last twelve months, insiders at the biotechnology company sold shares 2 times. They sold a total of 88,939 shares worth more than $7,786,780.48. The most recent insider tranaction occured on August, 30th when Director Roeland Nusse sold 8,939 shares worth more than $717,980.48. Insiders at Bio-Techne own 4.5% of the company. Learn More about insider trades at Bio-Techne.

Information on this page was last updated on 8/30/2023.

Roeland Nusse Insider Trading History at Bio-Techne

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/30/2023Sell8,939$80.32$717,980.4851,872View SEC Filing Icon  
8/23/2021Sell4,000$481.52$1,926,080.0013,612View SEC Filing Icon  
11/25/2019Sell8,347$219.33$1,830,747.5115,721View SEC Filing Icon  
See Full Table

Roeland Nusse Buying and Selling Activity at Bio-Techne

This chart shows Roeland Nusse's buying and selling at Bio-Techne by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bio-Techne Company Overview

Bio-Techne logo
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Read More

Today's Range

Now: $69.00
Low: $68.31
High: $69.33

50 Day Range

MA: $63.08
Low: $52.83
High: $69.41

2 Week Range

Now: $69.00
Low: $51.79
High: $89.91


1,141,883 shs

Average Volume

1,017,444 shs

Market Capitalization

$10.91 billion

P/E Ratio


Dividend Yield